Database : MEDLINE
Search on : androgens [Words]
References found : 45337 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 4534 go to page                         

  1 / 45337 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524555
[Au] Autor:Utter M; Chakraborty S; Goren L; Feuser L; Zhu YS; Foster DA
[Ad] Address:Department of Biological Sciences, Hunter College of the City University of New York, New York, NY, 10065, USA; Biochemistry Program, Graduate Center of the City University of New York, New York, NY, 10016, USA.
[Ti] Title:Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.
[So] Source:Cancer Lett;, 2018 Mar 07.
[Is] ISSN:1872-7980
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:Prostate cells are hormonally driven to grow and divide. Typical treatments for prostate cancer involve blocking activation of the androgen receptor by androgens. Androgen deprivation therapy can lead to the selection of cancer cells that grow and divide independently of androgen receptor activation. Prostate cancer cells that are insensitive to androgens commonly display metastatic phenotypes and reduced long-term survival of patients. In this study we provide evidence that androgen-insensitive prostate cancer cells have elevated PLD activity relative to the androgen-sensitive prostate cancer cells. PLD activity has been linked with promoting survival in many human cancer cell lines; and consistent with the previous studies, suppression of PLD activity in the prostate cancer cells resulted in apoptotic cell death. Of significance, suppressing the elevated PLD activity in androgen resistant prostate cancer lines also blocked the ability of these cells to migrate and invade Matrigel™. Since survival signals are generally an early event in tumorigenesis, the apparent coupling of survival and metastatic phenotypes implies that metastasis is an earlier event in malignant prostate cancer than generally thought. This finding has implications for screening strategies designed to identify prostate cancers before dissemination.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 45337 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523204
[Au] Autor:Haahr T; Esteves SC; Humaidan P
[Ad] Address:Department of Clinical Medicine, Aarhus University, Denmark and the Fertility Clinic Skive, Skive Regional Hospital, Skive, Denmark.
[Ti] Title:Individualized controlled ovarian stimulation in expected poor-responders: an update.
[So] Source:Reprod Biol Endocrinol;16(1):20, 2018 Mar 09.
[Is] ISSN:1477-7827
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Controlled ovarian stimulation with subsequent multi-follicular development continues to be a keystone in ART. Evidence supports an individualized approach to ovarian stimulation, usually involving combinations of ovarian reserve tests, body mass index and age to tailor the exogenous gonadotropin dose, and potentially adjuvant treatment aiming for high safety and a shortening of time to live birth. While stimulation and trigger concepts have been developed successfully in normo- and hyperresponder patients, the poor responder patient remains difficult to manage. However, recent advances in definition and classification of the expected poor ovarian responder patient might enable a more accurate and clinically useful interpretation of new treatment concepts in a more homogenous study population. In the present review, we discuss the classification of the expected poor ovarian responder patient as well as clinically useful measurements of efficacy for controlled ovarian stimulation, and finally, we discuss the evidence for clinical management of patients with expected poor ovarian response, including adjuvant treatments such as growth hormone, androgens, and LH activity.In conclusion, the best available evidence supports that the treatment of the expected poor ovarian response patient should be individualized in all steps of ART, including the choice of GnRH analogue, the gonadotropin type and dose, ovulation trigger, and the possible use of adjuvant therapies.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Process
[do] DOI:10.1186/s12958-018-0342-1

  3 / 45337 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29522931
[Au] Autor:Mezzullo M; Fanelli F; Di Dalmazi G; Fazzini A; Ibarra-Gasparini D; Mastroroberto M; Guidi J; Morselli-Labate AM; Pasquali R; Pagotto U; Gambineri A
[Ad] Address:Endocrinology Unit, Department of Medical and Surgical Sciences, Centre for Applied Biomedical Research (C.R.B.A.), S. Orsola-Malpighi Hospital, Alma Mater University of Bologna, Bologna, Italy.
[Ti] Title:Salivary cortisol and cortisone responses to short-term psychological stress challenge in late adolescent and young women with different hyperandrogenic states.
[So] Source:Psychoneuroendocrinology;91:31-40, 2018 Feb 24.
[Is] ISSN:1873-3360
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Hyperandrogenic disorders have been associated with psychological distress, reduced quality of life, anxiety and depression. The hypothalamic-pituitary-adrenal (HPA) axis plays a pivotal role in the adaptive response to stressor events. Salivary cortisol (SalF) and cortisone (SalE) testing have been proven to be useful in the evaluation of HPA-axis activity. This study investigated whether SalF and SalE responses to two putative stressor levels differed between the hyperandrogenic states in late adolescent and young women, thus measuring the HPA-axis adaptive response to acute stress events. We selected 161 drug-free females aged 16-19 years from a large population previously enrolled in a cross-sectional epidemiological study. Saliva was collected in the morning before and after two putative stressor events consisting in a self-filled questionnaire (weaker stressor) and in a structured interview plus physical examination by an endocrinologist (stronger stressor). SalF and SalE, as well as blood steroids, were assessed by liquid chromatography-tandem mass spectrometry. Subjects were subdivided into different groups according to the presence of: isolated menstrual irregularities (MI, oligo-amenorrhea; n = 22), isolated hirsutism (HIR, modified Ferriman-Gallwey score ≥ 8; n = 26), isolated hyperandrogenaemia (HT, testosterone >0.438 ng/mL; n = 14), and polycystic ovary syndrome (PCOS, MI with HIR and/or HT, n = 16). The remaining 83 apparently healthy subjects were used as controls. SalF and SalE significantly decreased after the weaker stressor, following the physiologic diurnal loss, in all the groups except for isolated HIR, where they remained unchanged (P = 0.091 and P = 0.118, respectively). In contrast, SalF and SalE remained unchanged after the stronger stressor in isolated MI, isolated HT and controls, whereas SalF increased significantly in isolated HIR (P = 0.011), and SalE increased significantly both in isolated HIR (P = 0.005) and in PCOS (P = 0.011) groups. SalF percentage variation in response to the stronger stressor was positively associated with systolic blood pressure in PCOS (P = 0.018), and both SalF and SalE percentage variations were positively associated with diastolic blood pressure in the isolated HIR group (P = 0.010 and P = 0.006, respectively). In addition, in the isolated HIR group, the SalF percentage variation was negatively associated with HDL cholesterol levels (P = 0.005). Finally, SalF and SalE percentage variations were positively associated with circulating androstenedione (P = 0.031 and P = 0.011, respectively) and DHEA (P = 0.020 and P = 0.003, respectively) in the isolated HIR group. In conclusion, this study demonstrates that hirsute and PCOS adolescent and young women are characterized by HPA-axis overactivity in response to stressful stimuli, as detectable by salivary glucocorticoid measurements. These data also indicate that the higher the HPA-axis activity, the higher the adrenal androgen output and the worse the metabolic profile.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  4 / 45337 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29522417
[Au] Autor:Sam S
[Ad] Address:University of Chicago Pritzker School of Medicine, Department of Medicine, Section of Endocrinology, 5841 S. Maryland Avenue, Chicago, IL 60637, USA, Phone: +773-702 5641, Fax: +773-702 7686.
[Ti] Title:Differential effect of subcutaneous abdominal and visceral adipose tissue on cardiometabolic risk.
[So] Source:Horm Mol Biol Clin Investig;, 2018 Mar 09.
[Is] ISSN:1868-1891
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:Metabolic and cardiovascular diseases are increasing worldwide due to the rise in the obesity epidemic. The metabolic consequences of obesity vary by distribution of adipose tissue. Visceral and ectopic adipose accumulation are associated with adverse cardiometabolic consequences, while gluteal-femoral adipose accumulation are negatively associated with these adverse complications and subcutaneous abdominal adipose accumulation is more neutral in its associations. Gender, race and ethnic differences in adipose tissue distribution have been described and could account for the observed differences in risk for cardiometabolic disease. The mechanisms behind the differential impact of adipose tissue on cardiometabolic risk have started to be unraveled and include differences in adipocyte biology, inflammatory profile, connection to systemic circulation and most importantly the inability of the subcutaneous adipose tissue to expand in response to positive energy balance.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  5 / 45337 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28456808
[Au] Autor:Batista RL; Rodrigues AS; Nishi MY; Feitosa ACR; Gomes NLRA; Junior JAF; Domenice S; Costa EMF; de Mendona BB
[Ad] Address:Unidade de Endocrinologia do Desenvolvimento, Disciplina de Endocrinologia e Metabologia do Hospital das Clnicas, Laboratrio de Hormnios e Gentica Molecular (LIM/42), Faculdade de Medicina, Universidade de So Paulo, So Paulo, Brazil.
[Ti] Title:Heterozygous Nonsense Mutation in the Androgen Receptor Gene Associated with Partial Androgen Insensitivity Syndrome in an Individual with 47,XXY Karyotype.
[So] Source:Sex Dev;11(2):78-81, 2017.
[Is] ISSN:1661-5433
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:There are only 2 patients with 47,XXY karyotype and androgen receptor (AR) gene mutation reported in the literature, and both are diagnosed as complete androgen insensitivity syndrome (CAIS). We report a 22-year-old female with 47,XXY karyotype and atypical external genitalia. Sequencing of AR revealed the heterozygous p.Asn849Lys*32 mutation, and extensive X chromosome microsatellite analysis showed homozygosity for Xp and heterozygosity for Xq, suggesting partial X maternal isodisomy. Partial androgen insensitivity syndrome (PAIS) developed in this case, probably because of the presence of the heterozygous AR mutation and random X- inactivation of the healthy allele. This is the first report of a female patient with 47,XXY karyotype and PAIS phenotype.
[Mh] MeSH terms primary: Androgen-Insensitivity Syndrome/genetics
Codon, Nonsense/genetics
Genetic Predisposition to Disease
Karyotype
Mutation/genetics
Receptors, Androgen/genetics
[Mh] MeSH terms secundary: Base Sequence
Exons/genetics
Female
Heterozygote
Homozygote
Humans
Male
Microsatellite Repeats/genetics
Young Adult
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (AR protein, human); 0 (Codon, Nonsense); 0 (Receptors, Androgen)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:170501
[St] Status:MEDLINE
[do] DOI:10.1159/000468957

  6 / 45337 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518100
[Au] Autor:Nair-Shalliker V; Egger S; Chrzanowska A; Mason R; Waite L; Le Couteur D; Seibel MJ; Handelsman DJ; Cumming R; Smith DP; Armstrong BK
[Ad] Address:Cancer Research Division, Cancer Council New South Wales, Sydney, Australia.
[Ti] Title:Associations between sun sensitive pigmentary genes and serum prostate specific antigen levels.
[So] Source:PLoS One;13(3):e0193893, 2018.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Melanoma and prostate cancer may share risk factors. This study examined the association between serum PSA levels, which is a risk factor for prostate cancer, and variants in some melanoma-associated pigmentary genes. METHODS: We studied participants, all aged 70+ years, in the Concord Health and Ageing in Men Project who had no history of prostatitis or received treatment for prostate disease (n = 1033). We genotyped variants in MC1R (rs1805007, rs1805008), ASIP (rs4911414, rs1015362), SLC45A2 (rs28777, rs16891982), IRF4 (rs12203592), TYRP1 (rs1408799), TYR (rs1126809, rs1042602), SLC24A2 (rs12896399), and OCA2 (rs7495174). Generalised linear dominant models with Poisson distribution, log link functions and robust variance estimators estimated adjusted percentage differences (%PSA) in mean serum PSA levels (ng/mL) between variant and wildtype (0%PSA = reference) genotypes, adjusting for age, body mass index, serum 25OHD levels and birth regions (Australia or New Zealand (ANZ), Europe or elsewhere). RESULTS: Serum PSA levels were strongly associated with advancing age and birth regions: mean PSA levels were lower in Europe-born (-29.7%) and elsewhere-born (-11.7%) men than ANZ-born men (reference). Lower %PSA was observed in men with variants in SLC45A2: rs28777 (-19.6;95%CI: -33.5, -2.7), rs16891982 (-17.3;95%CI:-30.4,-1.7) than in wildtype men (reference). There were significant interactions between birth regions and PSA levels in men with variants in MC1R (rs1805007; p-interaction = 0.0001) and ASIP (rs4911414; p-interaction = 0.007). For these genes %PSA was greater in ANZ-born men and lower in Europe- and elsewhere-born men with the variant than it was in wildtype men. In a post hoc analysis, serum testosterone levels were increased in men with MC1R rs1805007 and serum dihydrotestosterone in men with ASIP rs1015362. CONCLUSION: Men with SNPs in SLC45A2, who have less sun sensitive skin, have lower PSA levels. Men with SNPs in MC1R and ASIP, who have more sun sensitive skin, and were born in ANZ, have higher PSA levels. Androgens may modify these apparent associations of pigmentary genes and sun exposure with PSA levels. IMPACT: PSA levels and possibly prostate cancer risk may vary with sun sensitivity and sun exposure, the effects of which might be modified by androgen levels.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1371/journal.pone.0193893

  7 / 45337 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29475970
[Au] Autor:Morimoto LM; Zava D; McGlynn KA; Stanczyk FZ; Kang AY; Ma X; Wiemels JL; Metayer C
[Ad] Address:School of Public Health, University of California, Berkeley libbym@berkeley.edu.
[Ti] Title:Neonatal Hormone Concentrations and Risk of Testicular Germ Cell Tumors (TGCT).
[So] Source:Cancer Epidemiol Biomarkers Prev;, 2018 Feb 23.
[Is] ISSN:1538-7755
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Testicular germ cell tumor (TGCT) incidence has increased over the last 40 years in the United States. In contrast to TGCT among infants, it is hypothesized that TGCT in adolescents and young men is the result of sex steroid hormone imbalance during early fetal development. However, little is known about the neonatal period when abrupt hormonal changes occur, and direct supporting evidence is scarce due to the difficulties in obtaining pre-diagnostic specimens. METHODS: We conducted a population-based case-control study examining hormone levels at birth among 91 infants (0-4 years) and 276 adolescents (15-19 years) diagnosed with TGCT, and 344 matched controls. Estrogen and androgen levels were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) from archived newborn dried blood spots. Logistic regression models were used to estimate the association between each hormone level and TGCT risk. RESULTS: Higher levels of androstenedione were associated with increased TGCT risk among adolescents (OR: 2.33, 95% CI: 1.37-3.97 for highest vs. lowest quartile; p-trend=0.003) but not among infants (OR: 0.70, 95% CI: 0.28-1.77). A similar pattern was observed for testosterone (OR: 1.73, 95% CI: 1.00-3.00,) although the trend was not significant (p-trend=0.12). Associations were stronger among non-Hispanic white subjects, relative to Hispanics. There was no difference by tumor histologic subtype. Estriol (the only detectable estrogen) was not associated with TGCT risk in either age group. CONCLUSIONS: Higher levels of neonatal androgens were associated with increased risk of TGCT among adolescents, suggesting that early life hormone levels are related to the later development of TGCT.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  8 / 45337 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29457756
[Au] Autor:Amiri M; Kabir A; Nahidi F; Shekofteh M; Ramezani Tehrani F
[Ad] Address:a Students Research Committee, Department of Midwifery and Reproductive Health, School of Nursing and Midwifery , Shahid Beheshti University of Medical Sciences , Tehran , Iran.
[Ti] Title:Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis.
[So] Source:Eur J Contracept Reprod Health Care;23(1):64-77, 2018 Feb.
[Is] ISSN:1473-0782
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Nowadays, selection of COCs with maximum antiandrogenic effects is one the main issues in treatment of women with polycystic ovary syndrome (PCOS). OBJECTIVE: This systematic review and meta-analysis aimed to compare the effects of COCs on the clinical and biochemical parameters of hyperandrogenism (HA) in patients with PCOS. METHODS: Electronic databases (PubMed, Scopus, ScienceDirect and web of science) were searched from 1987 to November 2015 to identify clinical trials investigating effect of the various COCs on the clinical and biochemical parameters of HA in patients. In this meta-analysis, both fixed and random effect models were used. Potential sources of heterogeneity were explored by meta-regression and subgroup analyses. RESULTS: Findings showed that COC use for 3-12 months was significantly associated with an increase in sex hormone-binding globulin (SHBG) levels and a decrease in Ferriman-Gallwey (FG) score, total testosterone (TT), free testosterone (FT), androstenedione (A4) and dehydroepiandrosterone sulphate (DHEAS) levels. Type of progestin or duration of treatment had no important effects on declining androgen levels. Long-term use of COCs (6-12 months) was more effective in improving hirsutism, compared to short term. COCs containing cyproterone acetate (CPA) for 12 months had the strongest effect in improving hirsutism. CONCLUSIONS: This study shows that, in patients with PCOS, COCs can effectively improve biochemical and clinical parameters of HA. All COCs studies have similar effects on the hormonal profiles of these patients, and products containing CPA may be an effective treatment in hirsute patients with PCOS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.1080/13625187.2018.1435779

  9 / 45337 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29367455
[Au] Autor:Dumontet T; Sahut-Barnola I; Septier A; Montanier N; Plotton I; Roucher-Boulez F; Ducros V; Lefranois-Martinez AM; Pointud JC; Zubair M; Morohashi KI; Breault DT; Val P; Martinez A
[Ad] Address:GReD, Universit Clermont Auvergne, CNRS, INSERM, Clermont-Ferrand, France.
[Ti] Title:PKA signaling drives reticularis differentiation and sexually dimorphic adrenal cortex renewal.
[So] Source:JCI Insight;3(2), 2018 Jan 25.
[Is] ISSN:2379-3708
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The adrenal cortex undergoes remodeling during fetal and postnatal life. How zona reticularis emerges in the postnatal gland to support adrenarche, a process whereby higher primates increase prepubertal androgen secretion, is unknown. Using cell-fate mapping and gene deletion studies in mice, we show that activation of PKA has no effect on the fetal cortex, while it accelerates regeneration of the adult cortex, triggers zona fasciculata differentiation that is subsequently converted into a functional reticularis-like zone, and drives hypersecretion syndromes. Remarkably, PKA effects are influenced by sex. Indeed, testicular androgens increase WNT signaling that antagonizes PKA, leading to slower adrenocortical cell turnover and delayed phenotype whereas gonadectomy sensitizes males to hypercorticism and reticularis-like formation. Thus, reticularis results from ultimate centripetal conversion of adult cortex under the combined effects of PKA and cell turnover that dictate organ size. We show that PKA-induced progenitor recruitment is sexually dimorphic and may provide a paradigm for overrepresentation of women in adrenal diseases.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher

  10 / 45337 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28743567
[Au] Autor:Junior JFCR; Silva AS; Cardoso GA; Silvino VO; Martins MCC; Santos MAP
[Ad] Address:Universidade Federal do Piau(UFPI), Campus Universitrio Ministro Petrnio Portella, Department of Biophysics and Physiology, Teresina, PI, Brazil.
[Ti] Title:Androgenic-anabolic steroids inhibited post-exercise hypotension: a case control study.
[So] Source:Braz J Phys Ther;22(1):77-81, 2018 Jan - Feb.
[Is] ISSN:1809-9246
[Cp] Country of publication:Brazil
[La] Language:eng
[Ab] Abstract:BACKGROUND: There is evidence of hypertensive effects caused by anabolic androgenic steroids (AAS). A single exercise session promotes the acute reduction of blood pressure, but the effects of AAS on this phenomenon are unknown. OBJECTIVES: To investigate the post-exercise blood pressure response in androgenic-anabolic steroid users. METHODS: Thirteen AAS users (23.94.3 years old) and sixteen controls (22.14.5 years old) performed a session of aerobic exercise. Heart rate and blood pressure were assessed before exercise and during a 60min post-exercise resting period. Repeated ANOVA measures were used to determine differences between the groups. RESULTS: While the control group had a significant reduction in post-exercise systolic blood pressure of up to 13.911.6mmHg at 40min, this phenomenon was limited among AAS users who reached a maximum of 6.211.5mmHg at 60min. The between groups comparison revealed significant higher post-exercise hypotension (PEH) for the control group at 30min (-12.914.1mmHg versus -2.97.6mmHg), 40min (-13.911.6mmHg versus -2.58.3mmHg), 50min (-13.913.9mmHg versus -5.07.9mmHg) and 60min (-12.512.8mmHg versus -6.211.5mmHg). There was no significant diastolic PEH in any of the groups. CONCLUSIONS: This study demonstrated impaired systolic post-exercise hypotension as a new adverse effect of AAS usage.
[Mh] MeSH terms primary: Anabolic Agents/therapeutic use
Androgens/therapeutic use
Post-Exercise Hypotension/prevention & control
Post-Exercise Hypotension/physiopathology
Testosterone Congeners/therapeutic use
[Mh] MeSH terms secundary: Adult
Anabolic Agents/pharmacology
Androgens/pharmacology
Blood Pressure/drug effects
Case-Control Studies
Heart Rate/drug effects
Heart Rate/physiology
Humans
Systole/drug effects
Systole/physiology
Testosterone Congeners/pharmacology
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Anabolic Agents); 0 (Androgens); 0 (Testosterone Congeners)
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:170727
[St] Status:MEDLINE


page 1 of 4534 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information